NIKA PHARMACEUTICALS, INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that NIKA PHARMACEUTICALS, INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2023 | $0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2022 | $0 | Apr 10, 2023 |
| FY2021 | Dec 31, 2021 | $0 | Mar 3, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($76.4K) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($95.8K) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($64.8K) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($3.18M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($14.7K) | Apr 10, 2023 |
| FY2021 | Dec 31, 2020 | ($8.9K) | Mar 3, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($76.4K) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($95.8K) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($64.8K) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($3.18M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($14.7K) | Apr 10, 2023 |
| FY2021 | Dec 31, 2020 | ($8.9K) | Mar 3, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($79.7K) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($154.9K) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($64.8K) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $33.7K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $14.7K | Apr 10, 2023 |
| FY2021 | Dec 31, 2020 | ($8.9K) | Mar 3, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.0K | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $17.9K | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $19.6K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $864 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $399 | Apr 10, 2023 |
| FY2021 | Dec 31, 2020 | $1.6K | Mar 3, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $318.6K | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $239.2K | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $101.7K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $18.2K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $24.0K | Apr 10, 2023 |
| FY2021 | Dec 31, 2020 | $10.5K | Mar 3, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($297.6K) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($221.2K) | Mar 25, 2026 |
| FY2025 | Dec 31, 2023 | ($82.1K) | Mar 25, 2026 |
| FY2024 | Dec 31, 2022 | ($17.3K) | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | ($23.6K) | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | ($8.9K) | Apr 10, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.00M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($8.93M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($3.40M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($3.34M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $151.7K | Apr 10, 2023 |
| FY2021 | Dec 31, 2020 | $137.0K | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | ($128.1K) | Mar 24, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.9K | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $2.1K | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $19.6K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $864 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $399 | Apr 10, 2023 |
| FY2022 | Dec 31, 2020 | $1.6K | Apr 10, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 10, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2022 | Dec 31, 2022 | 0 | Apr 10, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Apr 10, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.05B | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | 1.05B | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | 876.09M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 876.09M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 396.09M | Apr 10, 2023 |
| FY2021 | Dec 31, 2020 | 13.20M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | 13.20M | Mar 24, 2021 |